CN Patent

CN117695285A — 一种jak激酶抑制剂药物组合物

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2024-03-15 · 2y expired

What this patent protects

一种JAK激酶抑制剂药物组合物，含有(3aR,5s,6aS)‑N‑(3‑甲氧基‑1,2,4‑噻二唑‑5‑基)‑5‑(甲基(7H‑吡咯并[2,3‑d]嘧啶‑4‑基)氨基)六氢环戊并[c]吡咯‑2(1H)‑甲酰胺或其可药用盐和复合辅料如纤维素‑乳糖的药物组合物，具有良好的稳定性、溶出度和生物利用度且其制备工艺简便。

USPTO Abstract

一种JAK激酶抑制剂药物组合物，含有(3aR,5s,6aS)‑N‑(3‑甲氧基‑1,2,4‑噻二唑‑5‑基)‑5‑(甲基(7H‑吡咯并[2,3‑d]嘧啶‑4‑基)氨基)六氢环戊并[c]吡咯‑2(1H)‑甲酰胺或其可药用盐和复合辅料如纤维素‑乳糖的药物组合物，具有良好的稳定性、溶出度和生物利用度且其制备工艺简便。

Drugs covered by this patent

Patent Metadata

Patent number
CN117695285A
Jurisdiction
CN
Classification
—
Expires
2024-03-15
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hengrui Medicine Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.